The U.S. Food and Drug Administration granted priority review to Exelixis Inc.'s supplemental new drug application for Cabometyx to treat patients with previously untreated advanced renal cell carcinoma.

The application is based on data from a phase 2 trial. The FDA will take a decision on the drug by Feb. 15, 2018.

On April 25, 2016, Cabometyx was approved by the agency to treat advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.